← Back to Search

Nevi undergoing biopsy per SOC for Mole

N/A
Waitlist Available
Research Sponsored by Orlucent, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1year
Awards & highlights
No Placebo-Only Group

Summary

The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.

Eligible Conditions
  • Mole
  • Epithelial Dysplasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Establish the performance of SFI
Secondary study objectives
To compare SFI to clinical diagnosis.
To establish the tolerability of SFI Testing by documenting minimal, transient events that occur with reagent application.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nevi undergoing biopsy per SOCExperimental Treatment1 Intervention
Subjects with Nevi who will as part of their standard of care, will undergo biopsy.

Find a Location

Who is running the clinical trial?

Orlucent, IncLead Sponsor
6 Previous Clinical Trials
1,469 Total Patients Enrolled
Cathy Shachaf, PhDStudy DirectorPresident
2 Previous Clinical Trials
686 Total Patients Enrolled
~58 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top